MODIFICATION
R -- Leadership Development
- Notice Date
- 5/24/2007
- Notice Type
- Modification
- NAICS
- 541611
— Administrative Management and General Management Consulting Services
- Contracting Office
- Department of Health and Human Services, Food and Drug Administration, Office of Acquisitions and Grants Services, 5630 Fishers Lane, Room 2129, Rockville, MD, 20857-0001, UNITED STATES
- ZIP Code
- 00000
- Solicitation Number
- RFQ-1028546
- Response Due
- 6/8/2007
- Archive Date
- 6/23/2007
- Small Business Set-Aside
- Total Small Business
- Description
- THE PURPOSE OF THIS AMENDMENT IS TO ADDRESS QUESTIONS AND PROVIDE RESPONSES. ****THE DUE DATE FOR PROPOSALS HAS BEEN EXTENDED TO JUNE 8, 2007*** 1. Do I need to have a GSA schedule to bid? A. You do not need a GSA schedule to bid. All mention of GSA in the RFQ are hereby deleted. 2. What is the correct solicitation number? A. The correct solicitation number is RFQ-1028546. All mention of other solicitation numbers are hereby deleted. 3. Are the two recommendations from previous customers to be submitted in writing and do they need to be in a specific format? A. Writing is fine and no specific format is needed. 4. Can we have access to the report published by the IOM referenced in the background section? A. Yes, unfortunately it can not be attached to this particular ammendment. Please email to keith.austin@fda.hhs.gov in order to receive a copy of the report. 5. Where does the Office of Translational Sciences fit within the Center fro Drug Evaluation and Research? It is not shown on the organization chart onthe website. A. Yes it is listed as a direct report to the Center Director. http://www.fda.gov/cder/cderorg.htm 6. How many people are a part of OTS? A. 234 7. How many people are in the targeted leadership group within OTS? A. 50 8. An assessment is referenced in Phase 1 - "Conduct assessment of current culture (via observations and interviews)." Can we determine what number and mix of interviews, focus groups, observations, document review, etc. we use? What is the availability of the target population likely to be in your given timeframe? A. Phase 1 assessment is limited to management: senior management 12, 38 other managers, total 50. 9. Do you envision creating a task group to support the selected vendor in developing the vision, strategy and communication plan? A. We envision partnering with you as the client in this effort, not creating key elements on our own. 10. How much time are OTS leaders and participants prepared to give to this effort? A. Up to 10% total depending on the work phase. 11. What senior leaders are supportive of/sponsoring this effort? A. Primary leadership is the immediate office for OTS. However, support is aligned to both CDER and FDA management. 12. What is the organizational structure? What is the current mechanism by which information is disseminated in the organization? What is the current forum in which leaders/managers interface? A. OTS has four functional groupings: Office of Biostatistics (OB), Office of Clinical Pharmacology (OCP), Critical Path for CDER, and CDER Research. Both OB and OCP are organized in a similar manner with 5-7 divisions each compose of several teams reflecting the disease/organ function nature of projects. 13. How are decisions made within the organization? A. Depends on the decision. New drug approval decisions are made through the clinical organization with OB and OCP serving as consultants. Management decisions in OTS are made in a traditional manner. 14. How many stakeholder/audience interviews do you anticipate? A. Approximately 20. 15. Are the deliverable dates in the Statement of Work hard and fast? A. No, they are negotiable as makes sense. 16. Are resumes and bios both required as part of the response or is there a preference of one or the other? A. Either is fine. 17. What is the size, age, location, and level of job and educational experience of the target audience of this change management initiative? Much is described above. A. Most people have a doctorate of some sort: MD, PhD, PharmD 18. Are there any other offices besides Translational Sciences responding to the IOM recommendations report? If so, which offices and what are they focusing on? A. Yes there are other offices; however we can discuss this as needed with the selected contractor. 19. What is the role and mission of the Office of Translational Sciences within Center for Drug Evaluation and Research? A. The mission is related to moving FDA towards mroe quantitatively based decisions. 20. Why is the Office of Translational Sciences chosen to lead this change management effort? A. OTS is choosing to do it to itself. We were not asked to do this work. 21. To whom does the Office of Translational Sciences report? A. Director, Center for Drug Evaluation and Research. 22. Is there a specific, existing GAP analysis that OTS has in mind for the cultural change initiative? A. No 23. Is there a specific, existing IDP program that OTS has in mind for the cultural change initiative? A. Yes 24. Is there a size limitation for the number of pages the technical response can be? A. A concise response is appreciated. 25. Is the Institute of Medicine a vendor for the FDA? Will the IOM be allowed to bid on this proposal given they shaped/wrote the requirements for this RFQ? A. In that the IOM was contracted to perform the ?IOM Report?, it?s likely they are a contractor. Conflict of interest would need to be discussed. Working with OTS while related to the IOM report is not in any way tied to FDA response to the report. 26. If you are requiring a fixed price, are you requesting the vendor to make assumptions with regards to scope? For example, are we to make our own assumptions/estimates as to the number of IDP?s, the number of leadership training sessions, the number of leadership coaching sessions and the number of skill development training sessions required or will you be providing more detail on the scope? A. Yes, see above answers.
- Place of Performance
- Address: 10903 New Hampshire Avenue, Silver Spring, Maryland
- Zip Code: 20993
- Country: UNITED STATES
- Zip Code: 20993
- Record
- SN01302302-W 20070526/070524220519 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |